Currently, the SE-related components recognized as cancer therapeutic targets are bromodomain containing 4 (BRD4), cyclin dependent kinase 7 (CDK7), E1A binding protein P300 (EP300), CDK8 and CDK19 [16]. The gene discussed is BRD4; the disease is cancer.